Print this page Close this page

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1446111

RaQualia Pharma Inc. - Product Pipeline Review - Q4 2010

Description:
RaQualia Pharma Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “RaQualia Pharma Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- RaQualia Pharma Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of RaQualia Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of RaQualia Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the RaQualia Pharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate RaQualia Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of RaQualia Pharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the RaQualia Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with RaQualia Pharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of RaQualia Pharma Inc. and identify potential opportunities in those areas.
Contents:

List of Tables
List of Figures
RaQualia Pharma Inc. Snapshot
RaQualia Pharma Inc. Overview
Key Information
Key Facts
RaQualia Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
RaQualia Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
RaQualia Pharma Inc. – Pipeline Products Glance
RaQualia Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
RaQualia Pharma Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
RaQualia Pharma Inc. – Drug Profiles
RQ-00000005
Product Description
Mechanism of Action
R&D Progress
RQ-00000007
Product Description
Mechanism of Action
R&D Progress
RQ-00000005
Product Description
Mechanism of Action
R&D Progress
RQ-00000007
Product Description
Mechanism of Action
R&D Progress
RQ-4
Product Description
Mechanism of Action
R&D Progress
RQ-9
Product Description
Mechanism of Action
R&D Progress
RQ-00000007
Product Description
Mechanism of Action
R&D Progress
RQ-00000008
Product Description
Mechanism of Action
R&D Progress
RQ-00000774
Product Description
Mechanism of Action
R&D Progress
RQ-00203066
Product Description
Mechanism of Action
R&D Progress
RQ-10
Product Description
Mechanism of Action
R&D Progress
Nav 1.7 Blocker Program
Product Description
Mechanism of Action
R&D Progress
RQ-00201894
Product Description
Mechanism of Action
R&D Progress
RQ-00202730
Product Description
Mechanism of Action
R&D Progress
RQ-00310941
Product Description
Mechanism of Action
R&D Progress
T-Ca (Cav3.2) Blocker Program
Product Description
Mechanism of Action
R&D Progress
TRPM8 Blocker Program
Product Description
Mechanism of Action
R&D Progress
RaQualia Pharma Inc. – Pipeline Analysis
RaQualia Pharma Inc. – Pipeline Products by Therapeutic Class
RaQualia Pharma Inc. Pipeline Products By Target
RaQualia Pharma Inc. – Pipeline Products by Route of Administration
RaQualia Pharma Inc. – Pipeline Products by Molecule Type
RaQualia Pharma Inc. – Recent Pipeline Updates
RaQualia Pharma Inc. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
RaQualia Pharma Inc. Detailed Deal Summary
Acquisition
Green Infra Acquires BP's Wind Business In India
Asset Finance
Green Infra Acquires 100 MW Wind Farms For $95 Million From BP
Green Infra Completes Project Financing Of $58 Million For Acquisition Of Three Wind Farm Projects From BP Energy, India
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed Wednesday, May 22, 2013
11:30:58 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

RaQualia Pharma Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1446111

Office Code

OC8DIQSOSSPXWS

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EURO€ 384.00
Electronic (PDF) - Site License EURO€ 769.00
Electronic (PDF) - Enterprisewide EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Wednesday, May 22, 2013
11:30:58 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)